Overview

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High- Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate progression-free survival (PFS) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with Investigator's choice of chemotherapy (liposomal doxorubicin, paclitaxel, topotecan, or nab-paclitaxel).

Phase:

Phase 3

Details

Lead Sponsor:

Corcept Therapeutics

Treatments:

Albumin-Bound Paclitaxel
Doxorubicin
Liposomal doxorubicin
Paclitaxel
Topotecan